Exelixis Partners its Oncology Drug Cabozantinib with Ipsen for US$200 M Upfront
By Heather Cartwright & Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 3 (Table of Contents)
Published: 29 Mar-2016
DOI: 10.3833/pdr.v2016.i3.2150 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for an impressive US$200 M upfront, Exelixis has granted Ipsen rights to develop and commercialise its lead cancer drug cabozantinib outside the US, Canada and Japan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS